Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Purpose
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
Condition
- Generalized Myasthenia Gravis
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Completion of a qualifying zilucoplan study
Exclusion Criteria
- With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted)
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental 0.3 mg/kg zilucoplan (RA101495) |
|
More Details
- Status
- Active, not recruiting
- Sponsor
- Ra Pharmaceuticals, Inc.